Setipiprant, a selective <scp>CRTH</scp>2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics

Abstract

Setipiprant at multiple oral doses was well tolerated and reduced both the allergen-induced LAR and the associated AHR in allergic asthmatics. Our findings confirm that CRTH2 may be a promising target for the treatment of allergic disorders.